0001593968-20-002229.txt : 20201120 0001593968-20-002229.hdr.sgml : 20201120 20201120163249 ACCESSION NUMBER: 0001593968-20-002229 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201118 FILED AS OF DATE: 20201120 DATE AS OF CHANGE: 20201120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Daniels Karen K. CENTRAL INDEX KEY: 0001530197 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36242 FILM NUMBER: 201332932 MAIL ADDRESS: STREET 1: 11455 EL CAMINO REAL, SUITE 310 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adamis Pharmaceuticals Corp CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 997-2400 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CELLEGY PHARMACEUTICALS INC DATE OF NAME CHANGE: 19950615 4 1 primary_01.xml PRIMARY DOCUMENT X0306 4 2020-11-18 0000887247 Adamis Pharmaceuticals Corp ADMP 0001530197 Daniels Karen K. C/O ADAMIS PHARMACEUTICALS CORPORATION 11682 EL CAMINO REAL, STE 300 SAN DIEGO CA 92130 false true false false VP of Operations Common Stock 2020-11-18 4 S false 5333 0.4061 D 149242 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4025 to $0.408, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4. /s/Robert O. Hopkins, Power of Attorney for Karen K. Daniels 2020-11-20